Latest Recell News

Page 3 of 3

AVITA Medical Boosts Revenue 30% in Q4 2024, Revises Credit Covenants

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

Ada Torres

14 Feb 2025

AVITA Medical Unveils Cohealyx, Boosting Burn Care Market Potential to $1.5B

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

Ada Torres

14 Feb 2025

AVITA Medical Accelerates Growth with New FDA Approvals and 30% Revenue Surge

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Ada Torres

14 Feb 2025

Browse the archive

Full archive

Nov 2026 Oct 2026 Sept 2026 Aug 2026 July 2026 June 2026 May 2026 Apr 2026